Abdul Rafae (@a_rafaemd) profile picture

Oncologist @SaintFrancisCancerCenter Heme-Onc Fellowship@UAMShealth | IM Board Certified | McLaren Flint-MSU IM Alumni | RMU Graduate | ๐Ÿ‡ต๐Ÿ‡ฐโ›น๐Ÿฝโ€โ™‚๏ธโšฝ๏ธ๐Ÿ

Tulsa, OK
Joined July 2020
Photo by Abdul Rafae (@a_rafaemd)Photo by Abdul Rafae (@a_rafaemd)
Day 3 #ASCO26 5 plenary highlights: 1. #PROTEUS: PeriOp/PostOp Apa in Prostate Ca 2. #SARC041: Adj Abema in dediff liposarcoma 3. #LIBRETTO432 : Adj Selpercatinib in NSCLC 4. #HARMONi6: 1L Ivonescimab in Sq mNSCLC 5. #RASolute302: 2L Daraxonrasib in Panc Ca @ASCO 1/6
2
50
3
98
12,059
Abdul Rafae retweeted
I put together a free guide on using AI the right way in medicine. How to use it as a teacher. Where the ethical line is. 45+ research databases. Formal AI courses from AMA, AAMC, Harvard, Stanford. For medical students, IMGs, residents, and fellows: linkedin.com/posts/faiz-anweโ€ฆ
8
37
185
12,655
JUST IN: The report we always look for every year: CANCER STATISTICS, 2026 New milestone with 5y Survival of 70%!!! Still a lot of room to improve but also excellent progress ! @AmericanCancer @CACancerJournal @DanaFarber acsjournals.onlinelibrary.wiโ€ฆ
5
133
7
306
28,158
Treatment of Multiple Myeloma: ASCOโ€“Ontario Health (Cancer Care Ontario) Living Guideline | Journal of Clinical Oncology @JCO_ASCO @ASCO #mmsm โžก๏ธ ascopubs.org/doi/10.1200/JCOโ€ฆ
1
19
1
31
4,236
When programs reward numbers, trainees chase numbers. When programs reward thinking, trainees become physicians.
๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต ๐—ณ๐—ผ๐—ฟ ๐˜๐—ต๐—ฒ ๐˜€๐—ฎ๐—ธ๐—ฒ ๐—ผ๐—ณ ๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต: The article highlights how academic medicine is drifting toward an โ€œabstract factoryโ€ model, where researchers, trainees, and institutions prioritize producing large numbers of abstracts and publications over meaningful, high-quality scholarship. ๐‘ช๐’๐’๐’‡๐’†๐’“๐’†๐’๐’„๐’† ๐’‚๐’ƒ๐’”๐’•๐’“๐’‚๐’„๐’• ๐’‚๐’„๐’„๐’†๐’‘๐’•๐’‚๐’๐’„๐’† ๐’˜๐’‚๐’” ๐’๐’๐’„๐’† ๐’‚ ๐’Ž๐’†๐’‚๐’๐’Š๐’๐’ˆ๐’‡๐’–๐’ ๐’Ž๐’‚๐’“๐’Œ๐’†๐’“ ๐’๐’‡ ๐’”๐’„๐’‰๐’๐’๐’‚๐’“๐’”๐’‰๐’Š๐’‘, ๐’ƒ๐’–๐’• ๐’Ž๐’‚๐’”๐’” ๐’”๐’–๐’ƒ๐’Ž๐’Š๐’”๐’”๐’Š๐’๐’๐’” ๐’‰๐’‚๐’—๐’† ๐’Š๐’๐’‡๐’๐’‚๐’•๐’†๐’… ๐’Š๐’•๐’” ๐’—๐’‚๐’๐’–๐’†. ๐‘ป๐’‰๐’Š๐’” โ€œ๐’๐’–๐’Ž๐’ƒ๐’†๐’“๐’” ๐’ˆ๐’‚๐’Ž๐’†โ€ ๐’…๐’Š๐’”๐’•๐’๐’“๐’•๐’” ๐’“๐’†๐’”๐’Š๐’…๐’†๐’๐’„๐’š ๐’†๐’—๐’‚๐’๐’–๐’‚๐’•๐’Š๐’๐’๐’”, ๐’…๐’Š๐’”๐’‚๐’…๐’—๐’‚๐’๐’•๐’‚๐’ˆ๐’†๐’” ๐’•๐’“๐’‚๐’Š๐’๐’†๐’†๐’” ๐’˜๐’Š๐’•๐’‰ ๐’‡๐’†๐’˜๐’†๐’“ ๐’ƒ๐’–๐’• ๐’‰๐’Š๐’ˆ๐’‰๐’†๐’“-๐’’๐’–๐’‚๐’๐’Š๐’•๐’š ๐’‘๐’“๐’๐’‹๐’†๐’„๐’•๐’”, ๐’‚๐’๐’… ๐’‘๐’“๐’†๐’”๐’”๐’–๐’“๐’†๐’” ๐’๐’•๐’‰๐’†๐’“๐’” ๐’•๐’ ๐’‘๐’“๐’Š๐’๐’“๐’Š๐’•๐’Š๐’›๐’† ๐’’๐’–๐’‚๐’๐’•๐’Š๐’•๐’š ๐’๐’—๐’†๐’“ ๐’Ž๐’†๐’‚๐’๐’Š๐’๐’ˆ๐’‡๐’–๐’, ๐’“๐’Š๐’ˆ๐’๐’“๐’๐’–๐’” ๐’“๐’†๐’”๐’†๐’‚๐’“๐’„๐’‰ ๐’‹๐’–๐’”๐’• ๐’•๐’ ๐’”๐’•๐’‚๐’š ๐’„๐’๐’Ž๐’‘๐’†๐’•๐’Š๐’•๐’Š๐’—๐’†. This pressure driven culture encourages superficial research, dilutes scientific rigor, and shifts focus away from curiosity, critical thinking, and true knowledge advancement. The authors warn that this trend negatively impacts medical education, mentorship, and the integrity of science, and they call for a cultural reset that values depth, originality, and real clinical or scientific impact over sheer volume. jamanetwork.com/journals/jamโ€ฆ
4
11
1
144
15,059
This slide perfectly illustrates the paradox of modern HR+ metastatic breast cancer management. On paper, the postโ€“CDK4/6 landscape is elegant and biologically rational: NGS-guided decisions, ESR1-targeted oral SERDs, PI3K/AKT pathway inhibitors, PARP inhibitors, and even CDK4/6 continuation strategies. Almost every resistance mechanism has a proposed solution. In real life, howeverโ€”in many countries, including my ownโ€”most of these red-highlighted options are simply not accessible. The algorithm exists, the evidence exists, the biomarkers existโ€ฆ but the treatments do not. So the question is unavoidable: who is this progress really for? If we cannot deliver these drugs to patients, daily discussions about ever-expanding therapeutic menus risk becoming purely theoretical exercises. Theoretical knowledge alone is not enough; translating it into practice is essential, but this is unfortunately not in the hands of physicians. It is a global problem. So, where were we? What were we supposed to give patients with ESR1 mutations, those with PIK3CA alterations, and those with co-mutations? And then the questions keep coming: what if the DFI is less than 12 months? If ctDNA turns positive before radiologic progressionโ€”was that SERENA-6 or PADA-1? After every conference, I find myself trapped in this paradox. Hopefully, one day everyone will have fair access to the treatments they deserve. Wishing you a nice weekendโ€”it was a good conference. #SABCS25
12
76
4
189
22,864
Management of Cancer During Pregnancy: ASCO Guideline It is a remarkably comprehensive guide that addresses every question thoroughly๐Ÿ‘‡ ascopubs.org/doi/10.1200/JCOโ€ฆ
1
96
2
211
13,011
In 2025, many important and long-awaited studies were published. I included them but kept the algorithms unchanged, as there are open questions about how these data will impact practice, particularly in early and metastatic HER2+ disease and mTNBC. @DFCI_BreastOnc #SABCS25
10
170
9
336
37,002
Itโ€™s time for #ASH25! Here is a๐Ÿ“ of ๐Ÿ”‘studies from #CommunityOncologists perspective. - #BRUINCLL313 - #WINDOW3 - #ALPINE - #MajesTEC3 - #MRD in Myeloma - #COBRA - #AUGMENT101 - #GimemaALL2820 - #VAYHIT2 - #VERIFY #mmsm #lymsm #leuksm #HemeTwitter @ASH_hematology
2
23
3
56
13,681
BCMA-Based Therapies in Multiple Myeloma #mmsm Summary of the approved drugs/combinations targeting BCMA with details on approval date, lines of therapy, supportive studies, common AEs as well as need for REMS Updated 10/2025
2
35
3
98
9,861
Wow. All the benefit of checkpoint inhibition in A-BRAVE (high-risk TNBC) was seen in patients with TILs โ‰ฅ 30%. No benefit with low TILs. Unbelievable that we didnโ€™t get to see the TILs data from KN522 yet. Hope weโ€™ll see them soon. Congrats @vitti10! #ESMO25 #ESMOAmbassadors
4
69
1
197
11,671
The bar is raised! Periop ๐Ÿฅช EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302* โœ…pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop โœ…2yr EFS & OS on par w DDMVAC in cis eligible -cis eligible EVP๐Ÿฅช trial *KNB15/EV304* readout awaited #ESMO25 โ€“ at Berlin, Germany
4
50
6
115
23,454
๐Ÿšจ #ESMO25 | ASCENT-03 (LBA20) ๐Ÿงฌ Sacituzumab Govitecan (SG) vs physicianโ€™s-choice chemo in 1L PD-L1-negative or IO-ineligible mTNBC Results (n = 558; median FU 13.2 mo): Median PFS: 9.7 mo vs 6.9 mo โ†’ HR 0.62 (0.50-0.78), p < 0.0001 โœ… ORR: 48.4 % vs 45.5 % Median DOR: 12.2 mo vs 7.2 mo OS: immature Safety: G3+ AEs โ‰ˆ 66 % vs 62 % Neutropenia 43 % / 41 %, diarrhea 9 %, anemia 16 % Tx discontinuation 4 % vs 12 % โ†’ better tolerability ๐Ÿ“ˆ Interpretation: SG delivers a clinically meaningful PFS gain (~3 mo) and more durable responses, with manageable toxicity. ๐Ÿ’ก Context: Comparable PFS to KEYNOTE-355 (IO + chemo โ‰ˆ 9.7 mo), showing ADC monotherapy can rival IO + chemo in PD-L1โ€“negative or IO-ineligible mTNBC. Looking forward to discussion on esmo day 3 #ESMO25 @myESMO @OncoAlert
6
1
17
4,881
One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases, anticipating the expansion of T-DXd to the curative setting, two Trop2 ADCs reaching first-line mTNBC, 2 novel ET-based combos, adjuvant CDK4/6i improving OS. See you in Berlin! #ESMOAmbassadors
6
78
4
256
33,783
~2 wks to #ESMO25! Hereโ€™s a๐Ÿ“of๐Ÿ”‘studies for GeneralOnc that could change/reinforce SoC: - #DESTINYBreast 05&11 - #monarchE & #NATALEE - #VIKTORIA1 - #FORTITUDE01 - #DYNAMIC3 - #STELLAR303 - #KN905 - #IMVigor011 - #PSMAddition - #MDTBridge #OncTwitter @myESMO @OncoAlert
3
72
4
203
27,135
๐Ÿ“ฃDurva-FLOT was added to NCCN guidelines of gastric and GEJ adenoca โœ…For PDL1 positive tumors, category 1 โœ…CPS or TAP โœ…PDL1 testing is recommended universal, not just for advanced disease #cancer #oncology #MedX #gastric @OncoAlert @ASCO @myESMO @brunolarvol @SuyogCancer
1
87
5
258
28,447